(Canada) Analysis - DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: Ethical Issues (eg. equity?)

 Blogger's Note: a second book (analysis of issues)

open access - NCBI Bookshelf

Show details

CADTH Optimal Use Report, No. 5.3c.

Duthie K, Bond K, Kaunelis D.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

• Contents

 Distributing the benefits and burdens fairly (equity)

Another consideration for the implementation of universal dMMR tumour testing for both treatment optimization and LS diagnosis is whether access to the necessary expertise and services is fairly distributed among the affected population regardless of income level, education, or cultural background. If it is found that the current system favours access only for those of a particular group (especially a privileged group) and that this injustice cannot be rectified, decision-makers would need to think carefully about implementing such a program.